Lavasani SM, Somlo G, Yost SE, Frankel PH, et al. Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer. Cancer 2022 Dec 14. doi: 10.1002/cncr.34589.
PMID: 36517940